Compare · head to head
Celltrion vs Eisai
Celltrion ranks higher overall — 360 rank 79 vs 70.
Eisai leads on Value (81 vs 48). Celltrion leads on Quality (54 vs 39) and Growth (65 vs 39). The two are close on Safety and Sentiment.
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | South Korea | Japan |
| Sector | Health Care | Health Care |
| Industry | Biotechnology | Pharmaceuticals |
| Size | Large | X-Large |
| ISIN | KR7068270008 | JP3160400002 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | ||
| Ranks | ||
| 360 | 79 | 70 |
| Value | 48 | 81 |
| Quality | 54 | 39 |
| Growth | 65 | 39 |
| Safety | 58 | 60 |
| Sentiment | 53 | 52 |
| Quality details | ||
| Profitability | 64 | 30 |
| Cash Truth | 45 | 48 |
Celltrion vs JW PharmaceuticalCelltrion vs Bora PharmaceuticalsCelltrion vs Innovent BiologicsCelltrion vs Jeil PharmaceuticalAdd a third stock →
Full analyses: Celltrion · Eisai
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100